US equities
|
NVDA
$240.24
▲+0.56%
SPCX
$173.73
▲+1.54%
MU
$1,063.07
▼-0.08%
MRVL
$281.37
▲+3.73%
AMD
$655.42
▲+3.75%
INTC
$114.29
▼-1.64%
SNDK
$1,671.20
▼-1.93%
AVGO
$377.29
▲+4.08%
NVDA
$240.24
▲+0.56%
SPCX
$173.73
▲+1.54%
MU
$1,063.07
▼-0.08%
MRVL
$281.37
▲+3.73%
AMD
$655.42
▲+3.75%
INTC
$114.29
▼-1.64%
SNDK
$1,671.20
▼-1.93%
AVGO
$377.29
▲+4.08%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Cullinan Therapeutics, Inc. - Common Stock
(NQ:
CGEM
)
16.98
+0.94 (+5.83%)
Delayed Quote
Updated: 1:05 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cullinan Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
December 12, 2024
Via
Benzinga
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
November 14, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
November 05, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
November 04, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
October 16, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
↗
September 25, 2024
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...
Via
Benzinga
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
September 17, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
September 16, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
September 14, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
↗
August 09, 2024
Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck's pipeline for treating B-cell malignancies and...
Via
Benzinga
CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024
↗
August 08, 2024
CGEM stock results show that Cullinan Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
June 01, 2024
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed...
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
May 24, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
May 23, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024
↗
May 15, 2024
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
April 29, 2024
Via
Benzinga
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
↗
April 29, 2024
Via
Benzinga
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
April 29, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
April 26, 2024
Via
Benzinga
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
April 26, 2024
Via
Benzinga
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday
↗
April 26, 2024
Via
Benzinga
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
↗
April 24, 2024
Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus...
Via
Benzinga
Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
↗
April 24, 2024
Via
Benzinga
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
April 24, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
April 17, 2024
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.
Via
Benzinga
United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
↗
April 17, 2024
U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday.
Via
Benzinga
Topics
Stocks
< Previous
1
2
3
4
5
6
7
Next >
